Cancers

Article	Citations
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review	478
A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis	313
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer	248
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy	224
The CCL5/CCR5 Axis in Cancer Progression	208
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies	202
Molecular Biology of Osteosarcoma	196
Organoid and Spheroid Tumor Models: Techniques and Applications	194
STING Agonists as Cancer Therapeutics	189
CA125 and Ovarian Cancer: A Comprehensive Review	187
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response	185
Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment	177
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies	174
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer	162
The Warburg Effect 97 Years after Its Discovery	158
Epidemiology of Glioblastoma Multiforme–Literature Review	157
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer	157
The Role of Macrophages in Cancer Development and Therapy	155
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance	154
The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities	151
Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer	150
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis	150
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies	148
Interleukin-1β and Cancer	148
Photodynamic Therapy: A Compendium of Latest Reviews	143

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors	141
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies	139
Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations	136
Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data	131
IL-12 Family Cytokines in Cancer and Immunotherapy	131
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma	129
Cannabidiol (CBD) as a Promising Anti-Cancer Drug	129
The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review	128
Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities	126
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance	125
DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy	123
The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy	122
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis	117
The Role of p53 Signaling in Colorectal Cancer	114
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis	114
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment	113
Carbon Ion Radiobiology	113
Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries	113
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer	111
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma	111
Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening	111
FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice	109
Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine	108
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach	108
Flavonoids in Cancer Metastasis	107
Non-Invasive Biomarkers for Early Detection of Breast Cancer	107
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma	107
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives	106
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)	106
Extracellular Glutathione Peroxidase GPx3 and Its Role in Cancer	105
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression	104
A Review of Circulating Tumour Cell Enrichment Technologies	104
The Role of Probiotics in Cancer Prevention	103
The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis	103
Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma	102
Tumor-Associated Macrophage Status in Cancer Treatment	102
The Role of Cancer-Associated Fibroblasts in Tumor Progression	102
The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)	101
Chemotherapy Side-Effects: Not All DNA Damage Is Equal	101
Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient	100
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment	99
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II	99
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer	98
RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field	98
Emerging Therapies for Hepatocellular Carcinoma (HCC)	97
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives	97
Immune Escape Mechanisms in Non Small Cell Lung Cancer	95
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy	93
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives	93
Mechanisms of Taxane Resistance	92

Arginine Signaling and Cancer Metabolism	92
Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis	91
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment	91
Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany	91
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy	90
Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations	89
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment	89
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity	89
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer	89
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma	89
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update	88
Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field	88
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Ration	88
Immune Resistance in Lung Adenocarcinoma	87
Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease	87
Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine	87
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management	87
MicroRNA Therapeutics in Cancer: Current Advances and Challenges	87
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines	86
Diffusion-Weighted Imaging in Oncology: An Update	86
Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets	86
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy	85
Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review	85
Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting	85
Mechanisms of Resistance to KRASG12C Inhibitors	85
Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study	84
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter	84
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy	84
Cancer and Aging: Two Tightly Interconnected Biological Processes	84
The Exciting New Field of HER2-Low Breast Cancer Treatment	83
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications	83
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions	83
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions	82
Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer	82
Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation	82
Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial–Mesenchymal Transition	82
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer	82
The Role of Artificial Intelligence in Early Cancer Diagnosis	81
A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy	81
Transfer Learning in Breast Cancer Diagnoses via Ultrasound Imaging	81
Glucose Transporters as a Target for Anticancer Therapy	81
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion	80
The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis	80
Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis	79
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations	78
Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment	78
3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs	78
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer	78
Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis	78
Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness	78
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far	77
Evolution of the Experimental Models of Cholangiocarcinoma	77
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy	77
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy	77
Cancer Stem Cells—Key Players in Tumor Relapse	77
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy	76
Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine	76
Radioresistance in Glioblastoma and the Development of Radiosensitizers	76
Neuroprotection of Radiosensitive Juvenile Mice by Ultra-High Dose Rate FLASH Irradiation	76
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment	76
Carbon Dots as Promising Tools for Cancer Diagnosis and Therapy	76
Transcription Factors in Cancer Development and Therapy	75
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021	75
The Functional Role of Extracellular Matrix Proteins in Cancer	75
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity	75
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches	75
Role of MSC in the Tumor Microenvironment	75
Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress	75
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review	75
Friend or Foe: S100 Proteins in Cancer	74
EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis	74
Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential	74
Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study	73
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment	73
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome	73
RNA-Binding Proteins in Cancer: Functional and Therapeutic Perspectives	73
Plasma-Treated Solutions (PTS) in Cancer Therapy	73
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology	73
The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy	73
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment	72

Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies	72
Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights	72
JAK-STAT Signalling Pathway in Cancer	72
MMP9: A Tough Target for Targeted Therapy for Cancer	72
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions	72
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics	71
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer	71
Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma	71
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer	71
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges	71
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials	71
Past, Present and Future of Oncolytic Reovirus	71
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview	71
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer	71
Radiomics of Liver Metastases: A Systematic Review	70
Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters	70
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?	70
Merkel Cell Polyomavirus and Merkel Cell Carcinoma	70
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling	70
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival	70
Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials	69
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions	69
Mechanisms of Resistance to Conventional Therapies for Osteosarcoma	69
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence	69
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice	69
Sex and Gender Disparities in Melanoma	69
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance	69
The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites	68
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers	68
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives	68
Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy	68
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis	68
Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?	68
Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance	68
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy	68
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy	68
How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH	67
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer	67
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview	67
Perspectives on the Role of Isoliquiritigenin in Cancer	67
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?	67
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma	67
The New Era of Immunotherapy in Gastric Cancer	67
Long Non-Coding RNA HOTAIR in Breast Cancer Therapy	67
Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis	67
Carotenoids in Cancer Apoptosis—The Road from Bench to Bedside and Back	67
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy	67
An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy	66
Pathology and Classification of SCLC	66
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy	66
Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update	66
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer	66
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies	65
Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies	65
MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review	65
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets	65
The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers	65
Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin	65
Hypoalbuminemia Reflects Nutritional Risk, Body Composition and Systemic Inflammation and Is Independently Associated with Survival in Patients with Colorectal Cancer	64
Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis	64
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations	64
Mechanosensitive Piezo Channels in Cancer: Focus on altered Calcium Signaling in Cancer Cells and in Tumor Progression	64
Cancer Extracellular Matrix Proteins Regulate Tumour Immunity	63
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies	63
Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance	63
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?	63
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors	63
Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis	62
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?	62
O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription: Emerging Roles in Cancer	62
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers	62
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia	62
The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma	62
New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis	62
Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing	61
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer	61
Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages	61
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy	61
Intracellular Porphyromonas gingivalis Promotes the Tumorigenic Behavior of Pancreatic Carcinoma Cells	61
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside	60
The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications	60
Trop2: Jack of All Trades, Master of None	60
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy	60
Matrix Stiffness Contributes to Cancer Progression by Regulating Transcription Factors	60
The Role of Chronic Inflammation in the Development of Breast Cancer	59
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives	59
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer	59
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?	59
Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients	59
Adoptive Immunotherapy beyond CAR T-Cells	59
The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment	59
Targeting CDK9 for Anti-Cancer Therapeutics	59
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons	59
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas	59
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives	59